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With the wide implementation of newborn screening for Cystic Fibrosis, infants are being diagnosed in
the presymptomatic phase of the disease. Nutritional deﬁciencies (hypoalbuminemia) and fat soluble
vitamins A, D and E deﬁciencies, due to pancreatic insufﬁciency and malabsorption, have been reported
in the past at the time of diagnosis.1,2 Rarely, infants with CF present with severe bleeding disorder,
secondary to vitamin K deﬁciency, in the ﬁrst months of life.3 To our knowledge, this is the ﬁrst case
report illustrating bleeding diathesis in a one month old infant with CF. He was diagnosed by newborn
screening and presented with a gastrointestinal bleeding due to vitamin K deﬁcient coagulopathy.
 2009 Published by Elsevier Ltd.1. Introduction
With the development and implementation of the newborn
screening (NBS) for Cystic Fibrosis (CF) it has become possible to
identify childrenwith CF, within the ﬁrst 1–2 months of life, mostly
in the presymptomatic phase of the disease.1 Nutritional deﬁ-
ciencies (hypoalbuminemia) and fat soluble vitamins A, D and E
deﬁciencies, due to pancreatic insufﬁciency and malabsorption,
have been reported in the past at the time of diagnosis in some
infants.1,2 Rarely, infants with CF present with severe bleeding
disorder, secondary to vitamin K deﬁciency, in the ﬁrst months of
life.3 Vitamin K deﬁciency has been reported in older children with
cystic ﬁbrosis not receiving routine vitamin K supplementation.4
Deﬁciency of vitamin K in childrenwith CF may be due to variety of
reasons, including inadequate dietary intake, maldigestion, and fat
malabsorption, decreased intestinal synthesis of vitamin K
following diarrheal disease or antibiotic administration.4
This report describes an infant with newly diagnosed CF who
developed bleeding diathesis. He presented with hematemesis and
blood in the stools at 4 weeks of age. Vitamin K deﬁcient bleeding
diathesis was conﬁrmed with laboratory testing and symptoms
resolved after vitamin K administration. This case is of interest
because of the unique presentation and a potential for life-threat-
ening complications associatedwith fat soluble vitamin deﬁcienciesealth System, Department of
diatric Pulmonary Medicine,
r., SPC5212, Ann Arbor, MI
936 7635.in young infants with CF if left untreated. It also illustrates the
important role of the newborn screening program for early diag-
nosis of CF and timely intervention with appropriate therapy.
2. Case report
TF is a 4 week old Caucasian male infant diagnosed with CF
through NBS. He had two mutations identiﬁed; R117H and G551D.
He was born at full term, had routine care, including vitamin K
prophylaxis at birth. At his initial clinic visit, on Day of Life (DOL)
#24, he was noted to be ‘‘gassy and colicky’’ with yellow-green, foul
smelling stools, 10 times a day. Weight gain was appropriate.
Physical exam was unremarkable, except for a full but nontender
abdomen, without organomegaly or palpable masses. Routine CF
care was prescribed, including the use of nebulized bronchodilator,
pancreatic enzymes and fat soluble vitamins supplementation. On
DOL #29 his parents noted a streak of bright red blood in his stool,
which was attributed to an anal ﬁssure. On the same day he had
emesis with brown streaks. Additional history suggested gastro-
esophageal reﬂux with frequent spitting up and fussiness after
feeding. He was otherwise feeding well, with decreased stool
frequency and improved gas symptoms. The brown streaks in the
emesis were attributed to mucosal irritation from GE reﬂux and
ranitidine was initiated. At a follow up visit on the next day, he
continued to show good weight gain. There was no recurrence of
the hematemesis. Occasional red-brown streaks were still noted in
the stool. Fat soluble vitamins supplementation was just initiated
on the day of the visit. Stool hemeoccult test was positive. He was
referred for blood work.
Table 1
Coagulation studies before and after administration of subcutaneous vitamin K.
At presentation 7.5 h post vitamin K Normal range
PT >100 s 11.7 s 9.5–11.7 s
aPTT 86.1 s 23 s 23–32 s
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and activated partial thromboplastin time (aPTT) was evident
(Table 1). In addition, a complete blood count, comprehensive
metabolic panel, and vitamin A level were all within appropriate
limits. Alpha tocopherol was found to be below the normal range
2.6 (3.8–18.4 mg/l). A cranial ultrasound was performed which
showed no hemorrhage. Vitamin K deﬁciency was diagnosed and
the infant received 1 mg subcutaneous injection of vitamin K. Next
laboratory evaluation, 7.5 h later, showed complete correction of
his coagulopathy (Table 1).
Further evidence that the coagulopathy was due to a vitamin K
deﬁciency was suggested by the levels of vitamin K dependent
clotting factors at the time of presentation. Factor VII and Factor X,
had an activity of less than 5% (normal range of 50–150%). Factor V,
a non-vitamin K dependent clotting factor had an activity of 91%
(normal range 50–150%). He was discharged home on daily ADEK
vitamins and oral vitamin K supplementation three times a week.
He had no further evidence of bleeding in the next few months.
Repeat PT and PTT continued to be within normal limits.3. Discussion
CF is the most common genetic disorder in Caucasians in the
United States, with incidence of 1 in 3500.5 The median age of
clinical diagnosis on the basis of signs and symptoms other than
meconium ileus is 14.5 months (interquartile range IQR: 4.2–65.0
months), compared with 0.2 month (IQR: 0–0.9 month) for meco-
nium ileus and 0.5 month (IQR: 0–0.9 month) for newborn
screening.6 Diagnosis on the basis of symptoms among infants is
associated with a >2-fold greater risk of medical complications
before diagnosis than diagnosis resulting from NBS.6 In 2004
newborn screening for CF was strongly recommended by both the
CF foundation and the CDC.7 That was followed by the majority of
the states in the US, implementing the addition of CF NBS to their
NBS panel. By the year 2010 all states are expected to provide CF
NBS to their infants. Michigan started NBS in 2007.
In the era of standard parenteral (intramuscular) vitamin K
prophylaxis at birth, vitamin K deﬁcient bleeding and in particular
late vitamin K deﬁcient bleeding (VKDB), between 2 and 12 weeks
of age is rare.8 It was recommended in an American Academy of
Pediatric Policy Statement that a single parental dose of 0.5–1 mg
(intramuscularly) most effectively prevent late VKDB in infants.8
Coagulopathy in infancy is a rare presentation of CF with a few
recent cases described in the English literature. CF infants 2–3.5
months of age with manifestation of intracranial hemorrhage3,9
and bruising and hematomas 10,11 have been described. We report
on an infant with newly diagnosed CF through NBS, presenting
with severe bleeding diathesis, manifesting as gastrointestinal
bleeding. PT and aPTT were signiﬁcantly elevated and vitamin K
dependent clotting factors were signiﬁcantly low, while the other
clotting factors were not affected, suggesting vitamin K deﬁcient
etiology. To our knowledge, this is the youngest CF patient reported,
presenting with severe bleeding diathesis, due to vitamin K deﬁ-
ciency. In this patient, routine intramuscular vitamin K adminis-
tration at birth failed to prevent vitamin K deﬁcient bleeding
diathesis. The Vitamin K deﬁciency could be secondary to either
insufﬁcient intake, especially with the patient exclusively being
breast fed, or due to malabsorption, given symptoms of pancreaticinsufﬁciency (PI). However, pancreatic supplementation was star-
ted at time of diagnosis with expected improvement in PI.
Vitamin K deﬁciency was identiﬁed as virtually universal in
older patients with CF and PI, prophylactic administration of
vitamin K was recommended in this population.12 The introduction
of the fat-soluble vitamin combination was speculated by the
authors to signiﬁcantly decrease the prevalence of vitamin K deﬁ-
ciency.12 The question remains as to how common fat soluble
vitamin deﬁciencies are in the infant CF population identiﬁed by
the newborn screen program and whether early supplementation
would be warranted. A study by Sokol et al. in 1991 was performed
to prospectively analyze the fat soluble vitamin deﬁciencies in
newborns with CF identiﬁed by newborn screen. These children
were receiving pancreatic enzyme supplementation as well as an
infant multivitamin. It was found that none of these infants had
vitamin K deﬁciency, based on negative PIVKA (proteins in vitamin
K absence) test.1 In 2002, the Consensus Report on Nutrition for
Pediatric Patients with Cystic Fibrosis,13 recommended daily
supplementationwith Vitamin K at a dose of 0.3–0.5 mg in addition
to the daily age appropriate dose of multivitamins. In addition, the
consensus states that fat soluble vitamin levels in patients diag-
nosed by newborn screening, do not need to be checked at the time
of diagnosis.
CF care givers need to be aware that severe coagulopathy could
happen in early infancy. The use of newborn screening to identify
the diagnosis helps establish early close monitoring and initiation
of appropriate therapies. Our case report emphasizes the necessity
of screening for vitamin K deﬁciency by measuring PT and aPTT, as
a surrogate13 as soon as the diagnosis is established. We think this
should be done especially in breast fed infants, regardless if the
infants received parenteral vitamin K at birth. It also demonstrates
the need for prompt recognition of symptoms of pancreatic insuf-
ﬁciency and initiation of supplemental fat-soluble vitamins and
pancreatic enzymes especially in breast fed infants.
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